Healios K.K. (4593) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Healios K.K. (4593:JPX), powered by AI.

Current Price
¥255
P/E Ratio
-12.4
Market Cap
27.5B
Sector
Healthcare
What is the Healios K.K. stock price forecast?

Healios K.K. is currently trading at ¥255. View real-time AI analysis on Alpha Lenz.

What is Healios K.K. insider trading activity?

View the latest insider trading data for Healios K.K. on Alpha Lenz.

What is Healios K.K.'s P/E ratio?

Healios K.K.'s P/E ratio is -12.4.

Healios K.K.

JPX · 4593
¥255-6(-2.30%)Market closedJPX regular session 09:00–15:00 JST
Ask about Healios K.K.'s future dividend policy...
Alpha Chat Insight

Healios K.K. trades at a P/E of -12.4 (undervalued) with modest ROE of -63.8%.

Ask for details

Company Overview

Healios K.K., a pioneering company in the field of biotechnology and regenerative medicine, focuses on advancing therapeutic solutions by leveraging stem cell technologies. Established in Japan, Healios K.K. seeks to address critical medical needs by developing innovative treatments, particularly in the areas of ophthalmology and organ regeneration. Its core initiatives include the development of cellular therapies to combat degenerative diseases and restore function where traditional medicine has limited efficacy. With strategic collaborations and cutting-edge research, Healios K.K. has positioned itself as a key player in the life sciences sector. The company not only contributes to the scientific community through its research and development efforts but also impacts the broader healthcare industry by exploring novel therapeutic options. Healios K.K.'s work stands at the frontlines of scientific discovery, aiming to transform patient care and improve quality of life for individuals suffering from chronic and life-altering conditions.

CEODr. Tadahisa S. Kagimoto M.D.
SectorHealthcare
IndustryBiotechnology
Employees65

Company Statistics

FY 2025

Profile

¥27,456,775,140Market Cap
¥104,000,000Revenue
0.00Shares Out
65Employees

Margins

-109.62%Gross
-1587.50%EBITDA
-3211.54%Operating
-2044.23%Pre-Tax
-2143.27%Net

Valuation

-12.38P/E
5.61P/B
264.01EV/Sales
-14.78EV/EBITDA
-8.24P/FCF

Growth (CAGR)

4.94%Rev 3Yr
30.96%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-14.27%ROA
-63.77%ROE
-12.33%ROIC

Financial Health

¥5,679,000,000Cash & Cash Equivalents
¥6,476,000,000Net Debt
248.11%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Healios K.K. (ticker: 4593) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 65 employees. Market cap is $27.5B.

The current price is 255 with a P/E ratio of -12.38x and P/B of 5.61x.

ROE is -63.77% and operating margin is -3211.54%. Annual revenue is $104M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Healios K.K. (4593) Stock Forecast 2026 ¥255 — Price, Financials & Analyst Targets | Alpha Lenz